Objective:To discuss the anti-rheumatoid arthritis activity and mechanism of hospital preparation Erteng Tongbi gran-ule ( ETTB) . Methods:The collagen-induced arthritis ( CIA) animal model in DBA/1 mice was established and treated with high, medium and low dosage of ETTB. Blank control, model control and methotrexate group were also established. The influences of ETTB on BMI, arthritis index, ankle joint destruction and expression of serum cytokine TNF-α and IL-6 in CIA mice were observed. Re-sults:Compared with the control group, ETTB at high dose (6g?kg-1) could significantly decrease the arthritis index of CIA mice (P<0. 05), and the joint damage on the 14th day was also significantly improved. ELISA results showed that ETTB at high dose could significantly inhibit the secretion of cytokine TNF-αand IL-6 when compared with the model group (P<0. 01). Conclusion:Hospital preparation ETTB has anti-rheumatoid arthritis activity, and its mechanism may be related with the inhibition of cytokine secretion.

Objective To explore the pharmaceutical care approaches for patients with lung cancer complicated with renal insufficiency receiving pemetrexed chemotherapy. Methods An elderly patient with lung cancer complicated with renal insufficiency receiving pemetrexed chemotherapy faced inevitable safety risks.Clinical pharmacists considered it as an intervention point, and provided individual pharmaceutical care. Results Clinical pharmacists fully assessed the safety risks of the case receiving pemetrexed chemotherapy with clinicians, assisted in improving the therapeutic regimen, and carried out medication education for the patient. No serious adverse drug reactions occurred in the patient, and anti-tumor efficacy was obtained. Conclusion For patients of lung cancer complicated with renal insufficiency receiving pemetrexed chemotherapy, clinical pharmacists should focus on creatinine clearance rate, and decide whether the combined use of platinum anti-tumor drugs, non steroidal anti-inflammatory drugs and zoledronic acid can be adopted, and follow-up on adverse drug reactions and anti-tumor efficacy.

Calculus Bovis (CB) is one of the precious traditional Chinese medicines (TCM) and has been widely used in oriental countries over 2000 years.It possesses a broad spectrum of pharmacological properties such as relieving fever,analgesic,diminishing inflammation,sedation,reducing blood pressure,recovering gallbladder functions,antioxygenation,and anti-tumor and improving immunity,et al.Due to the scarce resource and high price of natural CB,its substitutes,artificially synthesized CB and C.Bovis Sativus (CBS),also called in vitro cultured C.Bovis,have already been developed and widely used in medicine preparation.By using the literature material method,the current article explored literatures regard to pharmacological activities and clinical application of CB and its substitute,and the compound preparations were also included,from 1949 to 2016 in journals of domestic and foreign.All documents are summarized to provide a valuable reference for further basic or clinical research about CB and its substitute.

0.05),respectively;the total cost for Group A was significantly higher than in Group B (1 276.54 yuan vs.1 117.57 yuan,P

The preparation of Calculus bovis and its compounding preparations have been used widely in clinical practice.Traditionally,the forms of medicine were in raw material medicine way,preparing tablet,pill,powder or directly taking its powder.The main active ingredient of Calculus bovi were considered to be bilirubin and bile acids.However,the traditional formulations caused low bioavailability and wasted expensive herbs because its main component were insoluble in water.In recent years,many researchers have tried to use modern preparation technology to prepare its compounding formulations,such as solid dispersion technology,ultrafine grinding technology,powder coating technology,liposome encapsulation technology,or simplifying the prescription by using of known pharmacological effects of soluble components as substitutes.These methods were considered to be feasible to develop new formulations of Calculus bovis.In this paper,in order to provide reference of method and technology for the improvement of Calculus bovis compounding preparation and the development of new dosage form,ultramicrostructure,chemical composition,improvement methods and techniques of compounding preparation were analyzed.In addition,the relevant techniques and method of improving the formulation Calculus bovis compounding preparation in recent years were reviewed.

Natural Calculus Bovis,one of the precious traditional Chinese medicines,is the dried gallstone in bovine gallbladder,bile duct or hepatic duct.It is one of the essential components of the formulation of a variety of traditional Chinese medicines.Due to high price and rareness of natural Calculus Bovis,Chinese researchers have developed artificial Calculus Bovis,cultured Calculus Bovis and Calculus Bovis Sativus as substitutes of it.They are mainly composed of bilirubin,bile acids,amino acids and inorganic elements.Due to the co-existence of natural Calculus Bovisa and its substitutes in the market,and the complex composition of them,identification,quality control and material basis study of them are important issues in recent years.Currently,the quality control of them mainly focus on cholic acid and bilirubin.In order to fully solve the quality control problem of natural Calculus Bovis and its substitutes,researches on testing techniques of other bile acids or other components have already started.In this paper,research progress on the chemical compositions,quality control and the test technology of bilirubin,bile acids,amino acids and other components of Calculus Bovis are reviewed,in order to provide reference for further research of Calculus Bovis.

Objective:To analyze the anti-infection therapy for one lung cancer patient with agranulocytosis and fever after chemo-therapy to provide pharmaceutical care and support for the rational anti-infection drug use in the patient. Methods: Clinical pharma-cists analyzed the drugs used in the patient and provided pharmaceutical care for doctors according to the examination results and diag-nosis of the patient. Results:By participating in the treatment plan, clinical pharmacists ensured the treatment for the patient was safe and effective. Conclusion:Clinical pharmacists should assist doctors in making out the treatment plan according to patients’ situation in order to promote rational drug use in clinics and reflect the value of pharmaceutical care.

Calculus Bovis is a valuable traditional Chinese medicine and has been used for more than two thousand years in clinic with the effects of puring heart, sweeping phlegm, resuscitation, extinguishing wind and detoxification. Since the founding of the People's Republic of China, modern methods have been utilized by traditional Chinese medicine researchers in the resource identification, chemical components, pharmacodynamics, pharmacokinetics, pharmacy, clinical application, etc. It is their continually exploration that makes significant achievements for the modern research of Calculus Bovis. This article statistically analysed the literatures from 1949 to December 2015 in Pubmed, CNKI, Wanfang, Vip database etc. to review Calculus Bovis and its compound formulas, as well as its substitutes, quality control, formulation study, compound prescription, pharmacological mechanism and clinical research. The aim of this article is to provide a valuable reference for future developments and studies of Calculus Bovis.

Objective To explore the effect of hepatitis B virus(HBV) on the expression of apolipoprotein A1 (ApoA1) and its regulatory mechanism.Methods RT-PCR and Western blot were used to measure the expression of ApoA1 in HepG2 and HepG2.2.15 cells,serum ApoA1 and high density lipoprotein cholesterol(HDL-C) levels in patients with HBV infection and in healthy individuals were measured by biochemical analyzer,statistical difference was analyzed by SPSS13.0,HepG2 cells was co-transfected with ApoA1 promoter containing the luciferase gene and HBV infectious clone pHBV1.3,luciferase activity was measured,expression of ApoA1 in HepG2 cells was measured by RT-PCR and Western blot after transfected with pHBV1.3.Results Expression of ApoA1 mRNA and protein was lower in HepG2.2.15 cells than in HepG2 cells,serum ApoA1 and HDL-C levels were much lower in HBV patients as compared to healthy individuals( P＜0.05 ),HBV represses ApoA1 gene promoter activity,ApoA1 mRNA and protein expression in HepG2 cells.Conclusion HBV can inhibit the expression of ApoA1 bothin vivo and in vitro.